BLACK WEEKSVialer −15% · kit −10% · övrigt −5%med kodFri frakt inom Tyskland från €200

Den här sidan har översatts automatiskt och kan innehålla fel. Har du svenska som modersmål? Vi tar gärna emot din feedback och dina förbättringar.Skicka feedback

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), produktfoto

Labbrapport

PDF
Testad
Testad
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Labb
Analiza Białek
Datum
October 2026
Resultat
20.34 mg per tablet (20 mg label)
Beställningsnr.
Lösenord

Oberoende testad, kan verifieras med lösenordet direkt hos labbet.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Beställning

Styckpris - Fri frakt inom Tyskland från 200 € under Black Weeks
  • DHL med spårning
  • Diskret förpackning

4.6 av 5 på Trustpilot73 omdömen

I korthet

Tamoxifen (Nolvadex) i siffror

Nyckeltalen från vårt lexikon.

Hela lexikonartikeln
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Kunskap

Allt om Tamoxifen (Nolvadex)

FAQ

Vanliga frågor

Källor till varje svar: lexikonartikel

Har du fortfarande en fråga?

Skriv till oss, vårt team hjälper dig.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Jämförelser

Hur den står sig

Relaterat

Relaterade produkter